{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:08:18Z","timestamp":1790356098093,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03137-5","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:04:27Z","timestamp":1784102667000},"page":"2293-2300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Masataka","family":"Kubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimu","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Kayano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahito","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"JIKEI-YAYOI Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"3137_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","volume":"62","author":"D Westaby","year":"2022","unstructured":"Westaby D, Fenor de La Maza MLD, Paschalis A et al (2022) a new old target: androgen receptor signaling and advanced prostate cancer. Annu Rev Pharmacol Toxicol. 62:131\u201353","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"5","key":"3137_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700","journal-title":"Lancet Oncol"},{"issue":"32","key":"3137_CR3","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974\u20132986","journal-title":"J Clin Oncol"},{"issue":"20","key":"3137_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"20","key":"3137_CR5","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain M, Tombal B, Saad F et al (2023) Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 41(20):3595\u20133607","journal-title":"J Clin Oncol"},{"issue":"10336","key":"3137_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design. Lancet 399(10336):1695\u20131707","journal-title":"Lancet"},{"issue":"12","key":"3137_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132\u20131142","journal-title":"N Engl J Med"},{"issue":"21","key":"3137_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70029","volume":"13","author":"M Uemura","year":"2024","unstructured":"Uemura M, Kikukawa H, Hashimoto Y et al (2024) Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: phase 3 ARASENS subgroup analysis. Cancer Med 13(21):e70029","journal-title":"Cancer Med"},{"issue":"11","key":"3137_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/iju.15546","volume":"31","author":"F Urabe","year":"2024","unstructured":"Urabe F, Muramoto K, Yanagisawa T et al (2024) Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: a multicenter study. Int J Urol 31(11):1248\u20131255","journal-title":"Int J Urol"},{"issue":"5","key":"3137_CR10","doi-asserted-by":"publisher","first-page":"336.e1","DOI":"10.1016\/j.urolonc.2025.02.007","volume":"43","author":"F Urabe","year":"2025","unstructured":"Urabe F, Tashiro K, Muramoto K et al (2025) Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study. Urol Oncol 43(5):336.e1","journal-title":"Urol Oncol"},{"issue":"8","key":"3137_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u2013746","journal-title":"N Engl J Med"},{"issue":"1","key":"3137_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88207-6","volume":"11","author":"S Hwang","year":"2018","unstructured":"Hwang S, Kwon KT, Kim Y et al (2018) Usefulness analysis of the 2018 ASCO\/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy. Sci Rep 11(1):9048","journal-title":"Sci Rep"},{"issue":"4","key":"3137_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):427\u2013431","journal-title":"Clin Infect Dis"},{"key":"3137_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116264","volume":"236","author":"M Ong","year":"2026","unstructured":"Ong M, Suzuki H, Smith M et al (2026) Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: a phase III study. Eur J Cancer 236:116264","journal-title":"Eur J Cancer"},{"issue":"1","key":"3137_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.prnil.2024.11.003","volume":"13","author":"F Urabe","year":"2025","unstructured":"Urabe F, Kagawa H, Yanagisawa T et al (2025) Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study. Prostate Int 13(1):41\u201348","journal-title":"Prostate Int"},{"issue":"5","key":"3137_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10147-024-02501-7","volume":"29","author":"S Kimura","year":"2022","unstructured":"Kimura S, Shigeta K, Tamura S et al (2022) Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022. Int J Clin Oncol 29(5):559\u2013563","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"3137_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO-25-02938","volume":"44","author":"B Gyawali","year":"2026","unstructured":"Gyawali B, Bohlke K, Dickter JK et al (2026) WBC growth factors: ASCO guideline update. J Clin Oncol 44(9):812\u2013824","journal-title":"J Clin Oncol"},{"key":"3137_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyag058","author":"H Fukushima","year":"2026","unstructured":"Fukushima H, Yoshida S, Hirakawa A et al (2026) Bayesian interpretation of febrile neutropenia risk and primary granulocyte colony-stimulating factor prophylaxis during darolutamide triplet therapy. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyag058","journal-title":"Jpn J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03137-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:22Z","timestamp":1790355022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03137-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3137"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03137-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Takahiro Kimura has received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Sanofi, and Takeda.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board (33\u2013260[10878]).","order":2,"name":"Ethics","label":"Registry and the registration no. of the study\/trial","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Study registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Animal studies","group":{"name":"EthicsHeading","label":"Declarations"}}]}}